Latest Conference Articles

IASLC Conference Will Highlight PACIFIC Trial QoL Data on Durvalumab

Fred R. Hirsch, MD, PhD, provides highlights of the International Association for the Study of Lung Cancer 18th World Conference on Lung Cancer, leading with his excitement for updated quality-of-life data from the PACIFIC trial of patients with locally advanced, unresectable stage III non–small cell lung cancer.

Dr. Stone Discusses Monitoring MRD in AML

Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses monitoring minimal residual disease in acute myeloid leukemia.

Dr. Wong Discusses Monoclonal Antibodies in Plasma Cell Neoplasms

Sandy Wong, MD, assistant professor, Division of Hematology/Oncology, UCSF School of Medicine, discusses monoclonal antibodies in plasma cell neoplasms.

Mesa Highlights Guideline Updates in Myeloproliferative Neoplasms

The National Comprehensive Cancer Network guidelines for the management of polycythemia vera and essential thrombocythemia have been updated to create a more uniform system of management for healthcare providers to follow in clinical practice.

Immunotherapy Agents Leading Advancements in Metastatic Bladder Cancer

The therapeutic landscape is rapidly being altered by clinical trials of immunotherapy for patients with metastatic urothelial carcinoma, but simply changing the way quality of life is monitored could provide dramatic improvements in overall survival.

Control of Non-Muscle Invasive Bladder Cancer Recurrence With TURBT and Beyond

The aim of treating NMIBC is avoid the loss of the bladder and to prevent recurrence and progression to muscle-invasive disease.

CAR T Cells Highly Successful in ALL

Defined composition CAR T cells directed against CD19 have potent anti-tumor activity in B cell malignancies, including acute lymphocytic leukemia.

New AML Drugs Approved and Under Investigation in 2017

After nearly 40 years with little in the way of drug development for the treatment of acute myeloid leukemia, four new drugs have been approved by the FDA in 2017 for AML, and several promising agents are in development.

Treatment for Relapsed/Refractory Multiple Myeloma Based on Biology, Time to Relapse

The treatment approach for patients with relapsed/refractory multiple myeloma should be tailored based on biology of the disease, frailty of the patient, and comorbidities.

Managing Newly-Diagnosed Multiple Myeloma

Shaji K. Kumar, MD, discusses proper diagnosis, risk stratification, and personalized medicine for patients with newly-diagnosed multiple myeloma.

Dr. Mesa on Guideline Updates in Polycythemia Vera and Essential Thrombocythemia

Ruben Mesa, chair of the Division of Hematology and Medical Oncology at Mayo Clinic, discusses the guideline updates in polycythemia vera and essential thrombocythemia.

Dr. Winter Discusses Response in Follicular Lymphoma

Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses response in follicular lymphoma.

New Therapies Being Developed Rapidly for Relapsed Hodgkin Lymphoma

In relapsed classical Hodgkin lymphoma, the era of therapies post-brentuximab vedotin is developing rapidly.

Wierda Discusses Novel Combinations, Sequencing in CLL

William G. Wierda, MD, PhD, discusses the continued importance of ibrutinib, the promise for novel combinations, and the impact this progress has had on sequencing for CLL.

Data Emerges on Maintenance Therapies, Developing Treatments for Relapsed/Refractory FL

Survival for patients with grade 1 to 2 follicular lymphoma is now measured in decades to coincide with improvements in therapy.

Dr. Kumar on the Management of Newly Diagnosed Patients With Multiple Myeloma

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses the management of newly diagnosed patients with multiple myeloma.

Dr. Wierda Discusses Trials of Novel Combinations in CLL

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses trials of novel combinations on chronic lymphocytic leukemia.

Expert Urges for a More Multidisciplinary Approach to Bladder Cancer Care

Robert Jones, MD, discusses the future treatment landscape for patients with urothelial carcinoma in a more multidisciplinary setting.

Dr. Comperat on the Treatment Strategy for Neuroendocrine Tumors

Eva Comperat, MD, Hospital Tenon, discusses the treatment strategy for patients with neuroendocrine tumors (NETs).

Dr. Wagstaff on the Survival Benefit of Immunotherapy in Bladder Cancer

John Wagstaff, MD, professor at Swansea University Medical School, discusses the survival benefit of immunotherapy for patients with bladder cancer.

IMRT Linked With Low Rates of Pelvic Recurrence in Bladder Cancer

Delivering IMRT to the bladder and pelvic nodes in patients with node-positive bladder cancer or high-risk node-negative bladder cancer is feasible with patients experiencing low toxicity and demonstrating low pelvic nodal rates of recurrence

New Bladder Cancer Monitor Allows Non-invasive Routine Surveillance of NMIBC

A new procedure for monitoring RNA indicators of disease recurrence in urine samples from patients with a history of non-muscle invasive bladder cancer could spare these patients from undergoing multiple cystoscopies during routine follow-up.

Chemotherapy Retains Vital Role in Bladder Cancer Care

Although immunotherapy shows great promise in meeting the need for effective treatment of muscle invasive bladder cancer, chemotherapy continues to be an important tool in treating patients with this disease and other forms of bladder and urothelial cancer.

Dr. Konety on Guidelines for the Management of Bladder Cancer

Badrinath Konety, MD, MBA, department chair, Department of Urology, University of Minnesota, discusses the guidelines for the management of patients with bladder cancer.

Dr. De Santis on the Future Treatment Landscape for Bladder Cancer

Maria De Santis, MD, associate clinical professor at the University of Warwick, discusses the future treatment landscape for patients with bladder cancer.

Exploring the Role of Chemotherapy and Immunotherapy Combos in Urothelial Carcinoma

Andrea Necchi, MD, discusses the current role of immunotherapy and chemotherapy for patients with muscle-invasive bladder cancer.

Pembrolizumab Is Safe and Effective in Cisplatin-Ineligible Advanced Urothelial Carcinoma

As first-line therapy in cisplatin-ineligible advanced urothelial cancer, pembrolizumab (Keytruda) was safe and provided tumor reduction as well as durable responses.

Study Shows DAAs Are Not Associated With Increased HCC Recurrence Risk

Direct acting antivirals are a novel and completely oral hepatitis C therapy that is associated with a high response rate in hepatocellular carcinoma (HCC).

BLU-554 Associated With Improved Response in HCC

BLU-554 induced an overall response rate of 16% in patients with FGF19-positive hepatocellular carcinoma.

Dr. Cristofanilli on Endocrine Therapy for Breast Cancer

Massimo Cristofanilli, MD, professor of medicine, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, discusses endocrine therapy for patients with breast cancer.